COVID-19 rapid test FRCOG 020P

proteinSARS-COV-2clinical

The FREND™ COVID-19 Ag is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 directly from nasopharyngeal swab specimens directly from individuals suspected with COVID-19 by their healthcare provider. KEY FEATURES & BENEFITS - 2 steps | Easy to use - 94.12% & 100% | Positive & Negative Percent Agreement - Microfluidic Qualitative Immunoassay - LIS connectivity (data management) Microfluidic Qualitative Immunoassay FREND™ COVID-19 Ag The FREND™ COVID-19 Ag is a fluorescence immunoassay (FIA) for use with the FREND™ System. It is designed for the qualitative detection of the nucleocapsid protein of SARS-CoV-2 directly from nasopharyngeal swab specimens directly from individuals suspected with COVID-19 by their healthcare provider. Performance evaluation Clinical agreement study The total of 109 clinical samples (34 positive and 75 negative) confirmed with RT-PCR were tested with the FREND™ COVID-19 Ag. It shows 94.12% PPA (Positive Percent Agreement) and 100% NPA (Negative Percent Agreement) as shown below. Effective Data Management Laboratory Information System Connectivity In the event of a pandemic, the management of a vast amount of clinical result is important. However, many laboratories face the challenge in arranging the essential information effectively(1). The FREND™ System which is LIS compatible provide following features: Paperless Time-saving Automatic Data Transfer & Collect Convenient Data Management Can help monitoring (serosurveillance) Package 20 tests